Loading Please wait, logging in.
Join ALFA Member Login RSS Feed
Tagline Image
Bookmark and Share  

Antipsychotics Beneficial For Some Individuals With Alzheimer’s

A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.

Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.

Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City.  “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."

For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study  Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.

 
Suggested Articles:

9/15/2016
Active & Engaged Seniors, Community Awareness and Education, Federal Agency Activity, Memory Care Best Practices and Research, Memory Care Education, News
The National Institute on Aging has launched the third phase of an initiative to better understand Alzheimer’s disease by identifying and validating b...
9/15/2016
Facts and Figures, Human Resources, Memory Care Best Practices and Research, News, Research, Staffing & Performance
In 2012, more than 2.5 million Medicare beneficiaries had a dementia diagnosis, according to a new study published in JAMDA (Journal of American Medic...
9/15/2016
Executive Talent Management, Health Care, Human Resources, Human Resources and Organizational Development, Management, Memory Care Best Practices and Research, News, Organization Development, Staffing, Staffing & Performance
Senior Living Executive magazine recently spoke with memory care and human resource experts in senior living about what they look for in excellent mem...
9/7/2016
Active & Engaged Seniors, Community Awareness and Education, Core Principles, Disabilities, End of Life, Facts and Figures, Health and Wellness, News
At the 2016 South by Southwest Festival, visitors to the IBM Cognitive Studio were asked to respond to three questions. The results showed that out of...
9/1/2016
ALFA Events, HR Systems & Processes, Human Resources and Organizational Development, Managed Risk, News, Organizational Culture, Risk Management, Senior Living Industry Events
Willis Towers Watson, in partnership with Argentum, is hosting the annual Willis Towers Watson annual Senior Living Conference in Chicago, October 19-...
9/1/2016
Clinical Quality and Quality Care Delivery, Community Awareness and Education, Health and Wellness, Health Care, Knowledge Management, Medication Management, Medication Technology & Informatics, News
The Health and Human Services Department is seeking public input on its efforts to make it easier for patients’ medical records to follow them through...
8/25/2016
Clinical Quality and Quality Care Delivery, Facts and Figures, Federal Agency Activity, Medication Management, Medication Technology & Informatics, News, Science and Technology
Medical device companies will pay about $1 billion in fees to the Food and Drug Administration (FDA) from 2018 to 2022 to give the agency resources to...
8/25/2016
Clinical Quality and Quality Care Delivery, Community Awareness and Education, Facts and Figures, Health Care, Medication Management, Medication Technology & Informatics, News, Reports, Research
Overall prescription drug spending in the United States rose by 17 percent from 2013 to 2014, according to new data released by the Centers for Medica...
8/18/2016
Advocacy, Federal Agency Activity, Health and Wellness, Health Care, Legislation, Memory Care Best Practices and Research, Memory Care Education, News, Public Policy, Quality of Life, Regulations
This week, Sen. Richard Blumenthal (D-Conn.) sent a letter to the National Hockey League (NHL) Commissioner, urging the league to establish an indepen...
8/18/2016
Assisted Living, Clinical Quality and Quality Care Delivery, Core Principles, Facts and Figures, News, Reports, Research, Senior Living Options
Researchers from the University of North Carolina's Cecil G. Sheps Center for Health Services Research and School of Social Work, with funding from Th...
   
10/23/2012


Additional Resources